News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Ethical approval for LCT’s NTCELL® Phase I trial

Living Cell Technologies Limited
Company Announcement

Ethical approval for LCT’s NTCELL® Phase I trial

16 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has received ethical approval from the New Zealand Ministry of Health’s Health and Disability Ethics Committee to proceed with Phase I clinical trials of NTCELL® for Parkinson’s disease.
"We are extremely pleased to have received ethical approval in such an efficient timeframe," says Dr Andrea Grant, Chief Executive of LCT. "It means that LCT is still on track to commence NTCELL’s first in-human trials in Q1 2013.
LCT received regulatory authorisation from Medsafe to proceed with trials in October.

– Ends –

For further information: www.lctglobal.com

About Living Cell Technologies
Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need for immunosuppressant drugs.
LCT’s lead therapeutic candidate DIABECELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECELL is currently in Phase II clinical trials in both New Zealand and Argentina.
In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A$50m on formation, LCT vested the DIABECELL product and associated IP into the JV, while OPF vested A$25m to fund the final phase of development of DIABECELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECELL and the associated IP.
LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson's disease and stroke. NTCELL’s trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.
LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Game Review: Until Dawn - Pick Your Own Horrible Adventure

Supermassive Games’ Until Dawn sees a group of dumb sexy teenagers take a trip to a spooky mansion atop a mountain. It is, obviously, a horror game. However, the game is so ridiculous it turns out to be more of a comedy. More>>

John McBeth: Our World Cup All Blacks

Forty or fifty years ago nobody really had any idea of what the selectors had in mind. There were often several trials, which sometimes featured over 150 players, possibly an inter island match or a final trial, then we listened to the announcement of the team on radio. The players weren't flown into the capital for a parliamentary function... More>>

ALSO:

Game Review: Midsomer Murders Meets First Year Philosophy

Developed by The Chinese Room, Everybody's Gone to the Rapture sees the player exploring what appears to be a recently abandoned idyllic English village trying to figure out where everybody's gone. Spoiler: they've gone to the rapture. (On a serious note, this review contains plot spoilers.) More>>

Scoop Review Of Books: Clear Science

It was really after his move to Wellington, to Victoria University, that it became apparent that Sir Paul Cllaghan was much more than an eminent physicist... More>>

ALSO:

Francis Cook: Weekend SportzMania! All Blacks! Netball!

Sports were on all weekend. I normally don’t write about sports but with Richie McCaw tipped to be the next Prime Minister, and Colin Craig arguing sports are almost as important as politics, I thought “what better time to start!” More>>

ALSO:

Beervana: Aussie Pav Beer Declared Taste Of NZ

In a surprising upset, an Australian beer modelled on the pavlova, created by Brisbane brewery Newstead Brewing, the 250 Beers blog and Scratch Bar, has been announced the winner at the Beervana craft beer festival ‘Flag Brew’ competition, which challenged media and brewing teams to capture the distinctive taste of New Zealand. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news